Skip to main content
SpringerLink
Log in

Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains

  • Chapter
  • First Online:
Book cover Waldenström’s Macroglobulinemia

  • 590 Accesses

Abstract

Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder characterized by bone marrow infiltration of lymphoplasmacytic cells along with production of an IgM monoclonal protein in the serum. It can be associated to various complications related to tumor infiltration or to the serum monoclonal component.

Biology markers are essential for the diagnosis of WM, including the detection of the various manifestations of WM, for prognosis determination, monitoring of response to therapy and progression, and most interestingly for the decision of the optimal treatment. Indeed, in recent years, WM was characterized with two ground breaking discoveries: the description of MYD88 L265P mutation, a new hallmark of the diagnosis of WM, and in parallel, the identification of CXCR4 mutations as a marker of chemoresistance to certain treatments of WM that will ultimately guide the treatment choices in the very near future.

It is, thus, of great interest that we have seen progress in the biology of WM both at the serum protein level to investigate new tools and tests to better monitor the disease and at the molecular level to either improve diagnosis of WM or treatment decision making. In this chapter, we will describe the laboratory investigations and findings in WM.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, San Miguel JF, Branagan AR, Dimopoulos MA. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30(2):110–5. doi:10.1053/sonc.2003.50082.

    Article  PubMed  Google Scholar 

  2. Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia-Sanz R, Treon SP, Leblond V, Kyle RA, Barlogie B, Merlini G. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163–70. doi:10.1182/blood-2008-08-174961.

    Article  CAS  PubMed  Google Scholar 

  3. Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V, Fermand JP, Merlini G, Morel P, Morra E, Ocio EM, Owen R, Ghobrial IM, Seymour J, Kyle RA, Treon SP. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol. 2009;27(1):120–6. doi:10.1200/jco.2008.17.7865.

    Article  PubMed  Google Scholar 

  4. Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio EM, Morra E, Morel P, Anderson KC, Patterson CJ, Munshi NC, Tedeschi A, Joshua DE, Kastritis E, Terpos E, Ghobrial IM, Leleu X, Gertz MA, Ansell SM, Morice WG, Kimby E, Treon SP, Macroglobulinaemia VIIWoW. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160(2):171–6. doi:10.1111/bjh.12102.

    Article  PubMed  Google Scholar 

  5. Singh A, Eckardt KU, Zimmermann A, Gotz KH, Hamann M, Ratcliffe PJ, Kurtz A, Reinhart WH. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest. 1993;91(1):251–6. doi:10.1172/jci116178.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. McMullin MF, Wilkin HJ, Elder E. Inaccurate haemoglobin estimation in Waldenstrom’s macroglobulinaemia. J Clin Pathol. 1995;48(8):787.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Treon SP. How i treat Waldenstrom macroglobulinemia. Blood. 2009;114(12):2375–85. doi:10.1182/blood-2009-05-174359.

    Article  CAS  PubMed  Google Scholar 

  8. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol. 2003;4(11):679–85.

    Article  PubMed  Google Scholar 

  9. Ciccarelli BT, Patterson CJ, Hunter ZR, Hanzis C, Ioakimidis L, Manning R, Yang G, Xu L, Zhou Y, Sun J, Liu X, Tseng H, Cao Y, Sheehy P, Rodig SJ, Treon SP. Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011;11(1):160–3. doi:10.3816/CLML.2011.n.038.

    Article  CAS  PubMed  Google Scholar 

  10. Kyle RA, Greipp PR, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Therneau TM. Waldenstrom’s macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol. 2000;108(4):737–42.

    Article  CAS  PubMed  Google Scholar 

  11. Garcia-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A, Rodriguez-Garcia JA, Masso P, Perez-Aliaga A, Monteagudo MD, Navarro I, Moreno G, Toledo C, Alonso A, Besses C, Besalduch J, Jarque I, Salama P, Rivas JA, Navarro B, Blade J, Miguel JF, Spanish Group for the Study of Waldenstrom M, PETHEMA. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115(3):575–82.

    Article  CAS  PubMed  Google Scholar 

  12. Ghobrial IM. Are you sure this is Waldenstrom macroglobulinemia? Hematology. 2012;2012:586–94.

    PubMed  Google Scholar 

  13. Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R, D’Sa S, Soutar R, Waage A, Gulbrandsen N, Gregersen H, Low E, Haemato-oncology Task Force of the British Committee for Standards in Haematology UKMF, Nordic Myeloma Study G. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 2009;147(1):22–42. doi:10.1111/j.1365-2141.2009.07807.x.

    Article  CAS  PubMed  Google Scholar 

  14. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc. 2006;81(5):693–703.

    Article  PubMed  Google Scholar 

  15. Remstein ED, Hanson CA, Kyle RA, Hodnefield JM, Kurtin PJ. Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom’s macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. Semin Oncol. 2003;30(2):182–6. doi:10.1053/sonc.2003.50073.

    Article  PubMed  Google Scholar 

  16. Owen RG, Pratt G, Auer RL, Flatley R, Kyriakou C, Lunn MP, Matthey F, McCarthy H, McNicholl FP, Rassam SM, Wagner SD, Streetly M, D’Sa S, British Committee for Standards in H. Guidelines on the diagnosis and management of Waldenstrom macroglobulinaemia. Br J Haematol. 2014;165(3):316–33. doi:10.1111/bjh.12760.

    Article  PubMed  Google Scholar 

  17. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom’s macroglobulinemia. J Clin Oncol. 2005;23(7):1564–77. doi:10.1200/jco.2005.03.144.

    Article  PubMed  Google Scholar 

  18. Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R, Intergroupe Francophone du M. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101(4):1570–1. doi:10.1182/blood-2002-08-2436.

    Article  CAS  PubMed  Google Scholar 

  19. Ocio EM, Hernandez JM, Mateo G, Sanchez ML, Gonzalez B, Vidriales B, Gutierrez NC, Orfao A, San Miguel JF. Immunophenotypic and cytogenetic comparison of Waldenstrom’s macroglobulinemia with splenic marginal zone lymphoma. Clin Lymphoma. 2005;5(4):241–5.

    Article  PubMed  Google Scholar 

  20. Schop RF, Kuehl WM, Van Wier SA, Ahmann GJ, Price-Troska T, Bailey RJ, Jalal SM, Qi Y, Kyle RA, Greipp PR, Fonseca R. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood. 2002;100(8):2996–3001. doi:10.1182/blood.V100.8.2996.

    Article  CAS  PubMed  Google Scholar 

  21. Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C, Santos DD, Hatjiharissi E, Xu L, Leleu X, Tournilhac O, Patterson CJ, Manning R, Branagan AR, Morton CC. Characterization of familial Waldenstrom’s macroglobulinemia. Ann Oncol. 2006;17(3):488–94. doi:10.1093/annonc/mdj111.

    Article  CAS  PubMed  Google Scholar 

  22. Turner Jr CA, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell. 1994;77(2):297–306.

    Article  CAS  PubMed  Google Scholar 

  23. Nguyen-Khac F, Lambert J, Chapiro E, Grelier A, Mould S, Barin C, Daudignon A, Gachard N, Struski S, Henry C, Penther D, Mossafa H, Andrieux J, Eclache V, Bilhou-Nabera C, Luquet I, Terre C, Baranger L, Mugneret F, Chiesa J, Mozziconacci MJ, Callet-Bauchu E, Veronese L, Blons H, Owen R, Lejeune J, Chevret S, Merle-Beral H, Leblondon V, Groupe Francais d’Etude de la Leucemie Lymphoide Chronique et Maladie de W, Groupe Ouest-Est d’etude des Leucemie Aigues et Autres Maladies du S, Groupe d’Etude des Lymphomes de lA. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom’s macroglobulinemia. Haematologica. 2013;98(4):649–54. doi:10.3324/haematol.2012.070458.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Poulain S, Roumier C, Galiegue-Zouitina S, Daudignon A, Herbaux C, Aiijou R, Lainelle A, Broucqsault N, Bertrand E, Manier S, Renneville A, Soenen V, Tricot S, Roche-Lestienne C, Duthilleul P, Preudhomme C, Quesnel B, Morel P, Leleu X. Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. Am J Hematol. 2013;88(11):948–54. doi:10.1002/ajh.23545.

    Article  CAS  PubMed  Google Scholar 

  25. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, Arcaini L, Pinkus GS, Rodig SJ, Sohani AR, Harris NL, Laramie JM, Skifter DA, Lincoln SE, Hunter ZR. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012;367(9):826–33. doi:10.1056/NEJMoa1200710.

    Article  CAS  PubMed  Google Scholar 

  26. Kapoor P, Paludo J, Vallumsetla N, Greipp PR. Waldenstrom macroglobulinemia: what a hematologist needs to know. Blood Rev. 2015;29(5):301–19. doi:10.1016/j.blre.2015.03.001.

    Article  PubMed  Google Scholar 

  27. Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, Patterson CJ, Buhrlage SJ, Gray N, Tai YT, Anderson KC, Hunter ZR, Treon SP. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood. 2013;122(7):1222–32. doi:10.1182/blood-2012-12-475111.

    Article  CAS  PubMed  Google Scholar 

  28. Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123(18):2791–6. doi:10.1182/blood-2014-01-550905.

    Article  CAS  PubMed  Google Scholar 

  29. Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med. 2012;367(23):2255–7. doi:10.1056/NEJMc1211959#SA1.

    Article  CAS  PubMed  Google Scholar 

  30. Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, Corso A, Orlandi E, Bonfichi M, Gotti M, Pascutto C, Mangiacavalli S, Croci G, Fiaccadori V, Morello L, Guerrera ML, Paulli M, Cazzola M. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121(13):2522–8. doi:10.1182/blood-2012-09-457101.

    Article  CAS  PubMed  Google Scholar 

  31. Jimenez C, Sebastian E, Chillon MC, Giraldo P, Mariano Hernandez J, Escalante F, Gonzalez-Lopez TJ, Aguilera C, de Coca AG, Murillo I, Alcoceba M, Balanzategui A, Sarasquete ME, Corral R, Marin LA, Paiva B, Ocio EM, Gutierrez NC, Gonzalez M, San Miguel JF, Garcia-Sanz R. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom’s macroglobulinemia. Leukemia. 2013;27(8):1722–8. doi:10.1038/leu.2013.62.

    Article  CAS  PubMed  Google Scholar 

  32. Poulain S, Roumier C, Decambron A, Renneville A, Herbaux C, Bertrand E, Tricot S, Daudignon A, Galiegue-Zouitina S, Soenen V, Theisen O, Grardel N, Nibourel O, Roche-Lestienne C, Quesnel B, Duthilleul P, Preudhomme C, Leleu X. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood. 2013;121(22):4504–11. doi:10.1182/blood-2012-06-436329.

    Article  CAS  PubMed  Google Scholar 

  33. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, Morra E, Trojani A, Greco A, Arcaini L, Varettoni M, Brown JR, Tai YT, Anderson KC, Munshi NC, Patterson CJ, Manning RJ, Tripsas CK, Lindeman NI, Treon SP. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051–8. doi:10.1182/blood-2012-09-454355.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Roccaro AM, Sacco A, Jimenez C, Maiso P, Moschetta M, Mishima Y, Aljawai Y, Sahin I, Kuhne M, Cardarelli P, Cohen L, San Miguel JF, Garcia-Sanz R, Ghobrial IM. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014;123(26):4120–31. doi:10.1182/blood-2014-03-564583.

    Article  CAS  PubMed  Google Scholar 

  35. Hultcrantz M, Pfeiffer RM, Bjorkholm M, Goldin LR, Turesson I, Schulman S, Landgren O, Kristinsson SY. Elevated risk of venous but not arterial thrombosis in Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma. J Thromb Haemost. 2014;12(11):1816–21. doi:10.1111/jth.12724.

    Article  CAS  PubMed  Google Scholar 

  36. Mazurier C, Parquet-Gernez A, Descamps J, Bauters F, Goudemand M. Acquired von Willebrand’s syndrome in the course of Waldenstrom’s disease. Thromb Haemost. 1980;44(3):115–8.

    CAS  PubMed  Google Scholar 

  37. Hivert B, Caron C, Petit S, Charpy C, Fankam-Siaka C, Lecocq S, Zawadzki C, Susen S, Rusu M, Duhamel A, Tournilhac O, Goudemand J, Morel P. Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. Blood. 2012;120(16):3214–21. doi:10.1182/blood-2011-11-388256.

    Article  CAS  PubMed  Google Scholar 

  38. Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How i treat the acquired von Willebrand syndrome. Blood. 2011;117(25):6777–85. doi:10.1182/blood-2010-11-297580.

    Article  CAS  PubMed  Google Scholar 

  39. Lin P, Hao S, Handy BC, Bueso-Ramos CE, Medeiros LJ. Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. Am J Clin Pathol. 2005;123(2):200–5.

    Article  PubMed  Google Scholar 

  40. Murray DL, Ryu E, Snyder MR, Katzmann JA. Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clin Chem. 2009;55(8):1523–9. doi:10.1373/clinchem.2009.124461.

    Article  CAS  PubMed  Google Scholar 

  41. Treon SP, Gertz MA, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan AR, Garcia-Sanz R, Johnson S, Kimby E, Leblond V, Fermand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone MJ. Update on treatment recommendations from the Third International Workshop on Waldenstrom’s Macroglobulinemia. Blood. 2006;107(9):3442–6. doi:10.1182/blood-2005-02-0833.

    Article  CAS  PubMed  Google Scholar 

  42. Kimby E, Treon SP, Anagnostopoulos A, Dimopoulos M, Garcia-Sanz R, Gertz MA, Johnson S, LeBlond V, Fermand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone M, Blade J. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma. 2006;6(5):380–3. doi:10.3816/CLM.2006.n.013.

    Article  PubMed  Google Scholar 

  43. Ghobrial IM, Witzig TE. Waldenstrom macroglobulinemia. Curr Treat Options Oncol. 2004;5(3):239–47.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, Gertz MA, Eastern Cooperative Oncology G. Initial immunoglobulin M’flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an eastern cooperative oncology group study. Cancer. 2004;101(11):2593–8. doi:10.1002/cncr.20658.

    Article  CAS  PubMed  Google Scholar 

  45. Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R, Cook D, Songer J, Hill J, Kaden BR, Sharon D, Steiss R, Leleu X, Branagan AR, Badros A. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom’s macroglobulinemia: results of WMCTG Trial 03–248. Clin Cancer Res. 2007;13(11):3320–5. doi:10.1158/1078-0432.ccr-06-2511.

    Article  CAS  PubMed  Google Scholar 

  46. Gnemmi V, Leleu X, Provot F, Moulonguet F, Buob D. Cast nephropathy and light-chain deposition disease in Waldenstrom macroglobulinemia. Am J Kidney Dis. 2012;60(3):487–91. doi:10.1053/j.ajkd.2012.01.030.

    Article  PubMed  Google Scholar 

  47. Salviani C, Guido G, Serriello I, Giannakakis K, Rocca AR. Renal involvement in Waldenstrom’s macroglobulinemia: case report and review of literature. Ren Fail. 2014;36(1):114–8. doi:10.3109/0886022x.2013.832859.

    Article  PubMed  Google Scholar 

  48. Treon SP How I treat Waldenstrom macroglobulinemia. Blood 2015, doi: 10.1182/blood-2015-01-553974

  49. Vijay A, Gertz MA. Waldenstrom macroglobulinemia. Blood. 2007;109(12):5096–103. doi:10.1182/blood-2006-11-055012.

    Article  CAS  PubMed  Google Scholar 

  50. Wellwood J, Taylor K, Wright S, Bentley M, Eliadis P. Angioedema in the emergency department: a presentation of lymphoma. Emerg Med. 2001;13(4):465–8.

    Article  CAS  Google Scholar 

  51. Leleu X, Moreau AS, Weller E, Roccaro AM, Coiteux V, Manning R, Nelson M, Leduc R, Robu D, Dupire S, Hatjiharissi E, Burwick N, Darre S, Hennache B, Treon SP, Facon T, Gertz MA, Ghobrial IM. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008;49(6):1104–7. doi:10.1080/10428190802074619.

    Article  CAS  PubMed  Google Scholar 

  52. Leleu X, Xie W, Bagshaw M, Banwait R, Leduc R, Roper N, Weller E, Ghobrial IM. The role of serum immunoglobulin free light chain in response and progression in Waldenstrom macroglobulinemia. Clin Cancer Res. 2011;17(9):3013–8. doi:10.1158/1078-0432.ccr-10-2954.

    Article  CAS  PubMed  Google Scholar 

  53. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol. 2004;126(3):348–54. doi:10.1111/j.1365-2141.2004.05045.x.

    Article  CAS  PubMed  Google Scholar 

  54. Pattenden RJ, Davidson KL, Wenham PR. The value of serum free light chains in a case of Waldenstrom’s macroglobulinaemia that produces a type I cryoglobulinaemia. Ann Clin Biochem. 2009;46(Pt 6):531–2. doi:10.1258/acb.2009.009056.

    Article  CAS  PubMed  Google Scholar 

  55. Itzykson R, Le Garff-Tavernier M, Katsahian S, Diemert MC, Musset L, Leblond V. Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom’s macroglobulinemia. Haematologica. 2008;93(5):793–4. doi:10.3324/haematol.12107.

    Article  PubMed  Google Scholar 

  56. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy Jr JD, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110(3):827–32. doi:10.1182/blood-2007-01-067728.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Fourrier NJB et al. Nephelometric immunoassay measurements of IgMk and IgMλ for the assessment of patients with IgM monoclonal gammopathies. (abs. 120a). Clin Chem 56 (2);2010

    Google Scholar 

  58. Bradwell AR, Harding SJ, Fourrier NJ, Wallis GL, Drayson MT, Carr-Smith HD, Mead GP. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem. 2009;55(9):1646–55. doi:10.1373/clinchem.2009.123828.

    Article  CAS  PubMed  Google Scholar 

  59. Leleu X, Koulieris E, Maltezas D, Itzykson R, Xie W, Manier S, Dulery R, Boyle E, Gauthier J, Poulain S, Tatiana T, Panayiotidis P, Bradwell AR, Harding S, Leblond V, Kyrtsonis MC, Ghobrial IM. Novel M-component based biomarkers in Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011;11(1):164–7. doi:10.3816/CLML.2011.n.039.

    Article  CAS  PubMed  Google Scholar 

  60. Koulieris E, Kyrtsonis M, Maltezas D, Tzenou T, Mirbahai L, Kafassi N, Bartzis V, Dimou M, Georgiou G, Matsouka C, Pangalis G, Panayiotidis P, Bradwell A, Harding S. Quantification of serum IgM{kappa} and IgM{lambda} in patients with Waldenstrom’s macroglobulinemia (WM) at diagnosis and during disease course; clinical correlations. Blood (ASH Annual Meeting Abstract) 116;2010 Abstract 3004

    Google Scholar 

  61. Smogorzewska A, Flood JG, Long WH, Dighe AS. Paraprotein interference in automated chemistry analyzers. Clin Chem. 2004;50(9):1691–3. doi:10.1373/clinchem.2004.037499.

    Article  CAS  PubMed  Google Scholar 

  62. Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N. Treatment of Waldenstrom’s macroglobulinemia with rituximab. J Clin Oncol. 2002;20(9):2327–33.

    Article  CAS  PubMed  Google Scholar 

  63. Krishna VM, Carey RW, Bloch KJ. Marked increase in serum IgM during treatment of Waldenstrom’s macroglobulinemia with cladribine. N Engl J Med. 2003;348(20):2045–6. doi:10.1056/nejm200305153482025.

    Article  PubMed  Google Scholar 

  64. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18(2):317–24.

    Article  CAS  PubMed  Google Scholar 

  65. Treon SP, Agus TB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom’s macroglobulinemia. J Immunother. 2001;24(3):272–9.

    Article  CAS  Google Scholar 

  66. Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemia. Ann Oncol. 2004;15(10):1481–3. doi:10.1093/annonc/mdh403.

    Article  CAS  PubMed  Google Scholar 

  67. Nichols GL, Savage DG (2004) Timing of rituximab/fludarabine in Waldenström’s macroglobulinemia may avert hyperviscosity. Blood (ASH Annual Meeting Abstract) 104 2004;Abstract 4612

    Google Scholar 

  68. Leleu X, O’Connor K, Ho AW, Santos DD, Manning R, Xu L, Hatjiharissi E, Moreau AS, Branagan AR, Hunter ZR, Dimmock EA, Soumerai J, Patterson C, Ghobrial I, Treon SP. Hepatitis C viral infection is not associated with Waldenstrom’s macroglobulinemia. Am J Hematol. 2007;82(1):83–4. doi:10.1002/ajh.20724.

    Article  PubMed  Google Scholar 

  69. Ciccarelli BT, Yang G, Hatjiharissi E, Ioakimidis L, Patterson CJ, Manning RJ, Xu L, Liu X, Tseng H, Gong P, Sun J, Zhou Y, Treon SP. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):56–8. doi:10.3816/CLM.2009.n.014.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosures of Potential Conflicts of Interest

None.

Author information

Authors and Affiliations

  1. Maladies du sang, Hôpital Huriez, CHRU, Lille, France

    Guillemette Fouquet, Suzanna Schraen, Stéphanie Guidez & Xavier Leleu

  2. U837 Inserm, IRCL, CHRU, Lille, France

    Stéphanie Poulain, Elisabeth Bertrand & Xavier Leleu

  3. Hematology Section and Laboratory, University of Athens, Athens, Greece

    Efstathios Koulieris & Marie-Christine Kyrtsonis

  4. Hématologie et Thérapie cellulaire, Hôpital de la Mileterie, CHU, Poitiers, France

    Cécile Tomowiak & Xavier Leleu

  5. Department of Clinical Therapeutics, University of Athens, Athens, Greece

    Efstathios Kastritis

  6. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    Irene Ghobrial

  7. Hématologie, Hôpital Pitié-Salpêtrière, APHP, Paris, France

    Véronique Leblond

Authors
  1. Guillemette Fouquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stéphanie Poulain
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suzanna Schraen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Efstathios Koulieris
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elisabeth Bertrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stéphanie Guidez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cécile Tomowiak
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marie-Christine Kyrtsonis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Efstathios Kastritis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Irene Ghobrial
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Véronique Leblond
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Xavier Leleu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xavier Leleu .

Editor information

Editors and Affiliations

  1. Haematology, Hôpital Pitié-Salpêtriêre, Paris, France

    Véronique Leblond

  2. Dana Farber Cancer Institute, Boston, Massachusetts, USA

    Steve Treon

  3. School of Medicine, University of Athens, Athens, Greece

    Meletios Dimoploulos

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Fouquet, G. et al. (2017). Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains. In: Leblond, V., Treon, S., Dimoploulos, M. (eds) Waldenström’s Macroglobulinemia. Springer, Cham. https://doi.org/10.1007/978-3-319-22584-5_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22584-5_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22583-8

  • Online ISBN: 978-3-319-22584-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation